Before 2019, Blythe Adamson, a senior quantitative scientist at Flatiron Health, had never attended an annual meeting of the American Society of Clinical Oncology.
The FDA Oncology Center of Excellence announced a pilot program to help physicians get access to unapproved therapies for patients with cancer.
The mCODE initiative, developed by American Society of Clinical Oncology and its partners, aims to optimize electronic health records to answer research questions on drug efficacy and patient outcomes.
Project ECHO, a service that provides physicians in rural areas with access to multidisciplinary expertise, will soon announce partnerships with four cancer centers—Dana-Farber Cancer Institute, Mayo Clinic Cancer Center, University of New Mexico Comprehensive Cancer Center, and Yale Cancer Center.
As the team lead by surgeon Stephen Chagares prepared a protocol for robotically-assisted mastectomy, the Institutional Review Board at Monmouth Medical Center provided guidance “every step of the way,” said Nicholas Fotopoulos, a research coordinator and an undergraduate at Princeton University in his sophomore year.
When NCI renewed the Comprehensive Cancer Center designation for Rutgers Cancer Institute of New Jersey, it also acknowledged that the institution's catchment area now covers the entire state of New Jersey, having expanded from roughly three counties around its home location of New Brunswick.
Georgetown’s Weiner and Hackensack’s Pecora tell us how they created a consortium spanning 233 miles
Georgetown's Louis M. Weiner and Hackensack's Andrew L. Pecora started to discuss forming a consortium in 2011, roughly at the time when it became clear that conferencing and data transfer technologies were making it possible for cancer centers located hundreds of miles apart to operate in a coordinated manner.
Syapse, a precision medicine company with a data sharing network, has announced a collaboration with Amgen to use analytics and real world evidence to support drug development.
MD Anderson is the first institution to address the interrelated problems of theft of intellectual property, violation of ethics of NIH peer review, and researchers' failure to disclose foreign affiliations and sources of funding.
As MD Anderson investigates reports of wrongdoing by its faculty members, it does so with full understanding that the stakes are as high as it gets: the integrity of the NIH peer review system, MD Anderson's good name, and the future of cancer research.
